Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant

Clinical Ophthalmology

Volumn 4, Issue 1, 2010, Pages 1423-1426

  Myung, Jane S ^a   Aaker, Grant D ^a   Kiss, Szilárd ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Corticosteroids; Dexamethasone implant; Ozurdex; Uveitis

Indexed keywords

DEXAMETHASONE; PREDNISOLONE; PREDNISONE; TRIAMCINOLONE;

ADULT; AGED; ANTERIOR EYE CHAMBER; ANTIINFLAMMATORY ACTIVITY; CASE REPORT; CATARACT; CONJUNCTIVAL HEMORRHAGE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; EYE FUNDUS; EYE PHOTOGRAPHY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; IMPLANT; INJECTION SITE BLEEDING; INTRAOCULAR PRESSURE; MALE; MEDICAL RECORD REVIEW; NONINFECTIOUS POSTERIOR UVEITIS; OPTICAL COHERENCE TOMOGRAPHY; PAPILLITIS; RETINA DETACHMENT; RETINA VASCULITIS; REVIEW; SARCOIDOSIS; SIDE EFFECT; SUBRETINAL FLUID; SUSTAINED RELEASE PREPARATION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UVEITIS; VISUAL ACUITY; VOGT KOYANAGI SYNDROME;

EID: 78650696375     PISSN: 11775467     EISSN: 11775483     Source Type: Book Series    
DOI: 10.2147/OPTH.S15696     Document Type: Review

References (11)

1. van Kooji B, Rothova A, de Vries P. The pros and cons of intravitreal triamcinolone injections for uveitis and inflammatory cystoid macular edema. Ocul Immunol Inflamm. 2006;14:73-85.
2. Goldstein DA, Godfrey DG, Hall A, et al. Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol. 2007;125:1478-1485.
3. Kupperman BD, Blumenkranz MS, Haller JA, et al. Dexamethasone DDS Phase II Study Group. Randomized controlled study of an intraveitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007;125:309-317.
4. Williams GA, Haller JA, Kupperman BD, et al. Dexamethasone DDS Phase II Study Group. Dexamethasone Posterior-Segment Drug Delivery System in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol. 2009;147:1048-1054.
5. Haller JA, Kupperman BD, Blumenkranz MS, et al. Dexamethasone DDS Phase II Study Group. Randomized controlled trial of intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol. 2010;128:289-296.
6. Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131:647-652.
7. Karacorlu M, Arf Karacorlu S, Ozdemir H. Intravitreal triamcinolone acetonide in Vogt-Koyanagi-Harada syndrome. Eur J Ophthal. 2006;16:481-483.
8. Andrade RE, Muccioli C, Farah ME, Nussenblatt RB, Belfort R. Intravitreal triamcinolone in the treatment of serous retinal detachments in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 2004;137: 572-574.
9. Khalifa Y, Loh AR, Acharya NR. Fluocinolone acetonide intravitreal implants in Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2009;17:431-433.
10. United States Food and Drug Administration Website. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search. DrugDetails. Accessed 2010 Sep 30.
11. Haller JA, Bandello F, Belfort R Jr, et al. OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117:1134-1146.